---
title: "Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Pharmacokinetics"
description: "Formulary evidence on Deucrictibant (PHA121, PHA-022121) in On-demand treatment of hereditary angioedema attacks: Pharmacokinetics. Topics: Single ascending doses of oral solution in healthy volunteers: absorption, dose proportionality, and half-life; Single ascending doses of oral solution in healthy volunteers: pharmacokinetic parameters; Food effect after a single 22 mg dose of oral solution; Company summary of phase 1 pharmacokinetics with and without food; 9 further topics. 13 evidence topics quoted from 11 sources."
canonical: "https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description/pharmacokinetics"
published: "2026-11-18T22:35:03-05:00"
modified: "2026-11-18T22:35:03-05:00"
---

# Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Pharmacokinetics

<a id="heading-2.1.2.6.3"></a>

## 2.1.2.6.3 Pharmacokinetics

<a id="topic-2.1.2.6.3-1"></a>

### Single ascending doses of oral solution in healthy volunteers: absorption, dose proportionality, and half-life

> “PHA-022121 was very rapidly absorbed and reached peak plasma levels within 30 to 60 minutes after dosing in all subjects under fasted conditions. The systemic exposure was dose proportional with a mean t1/2 ranging from 3.5 to 5.6 h between doses.”
> “Plasma levels for PHA-022121 reached therapeutic efficacious threshold concentration”
> “within 15 min for all doses and were maintained for approximately 12 h with doses of 12 and 22 mg.”

Source: [Lu et al. (2020)](https://ir.pharvaris.com/static-files/0361cd85-6000-490b-932b-d305e1f3ca1b)

<a id="topic-2.1.2.6.3-2"></a>

### Single ascending doses of oral solution in healthy volunteers: pharmacokinetic parameters

| Parameter | 1 mg fasted | 2 mg fasted | 4.5 mg fasted | 12 mg fasted | 22 mg fasted | 22 mg after high-calorie, high-fat breakfast |
| --- | --- | --- | --- | --- | --- | --- |
| Cmax, ng/mL, mean (SD) | “11.1 (4.03)” | “19.8 (3.70)” | “32.9 (7.66)” | “97.3 (28.1)” | “213 (49.5)” | “145 (56.2)” |
| AUClast, ng.h/mL, mean (SD) | “33.0 (25.9)” | “66.0 (27.0)” | “129 (56.5)” | “369 (194)” | “681 (113)” | “1015 (490)” |
| t1/2, h, mean (SD) | “3.49 (1.32)” | “4.26 (1.91)” | “4.36 (1.29)” | “4.25 (0.831)” | “5.61 (0.707)” | “5.31 (1.54)” |
| CL/F, L/h, mean (SD) | “42.3 (25.4)” | “33.8 (11.9)” | “37.6 (11.1)” | “40.9 (20.7)” | “31.5 (5.60)” | “25.3 (9.77)” |

Source: [Lu et al. (2020)](https://ir.pharvaris.com/static-files/0361cd85-6000-490b-932b-d305e1f3ca1b)

<a id="topic-2.1.2.6.3-3"></a>

### Food effect after a single 22 mg dose of oral solution

> “Administration of the 22 mg dose with a HCHF breakfast led to a 32% lower Cmax, a 49% higher AUClast, and a delay of median tmax by approximately 2 h.”

Source: [Lu et al. (2020)](https://ir.pharvaris.com/static-files/0361cd85-6000-490b-932b-d305e1f3ca1b)

> “After a 22 mg dose, mean Cmax of PHA-022121 was 32% lower after a high calorie high fat (HCHF) breakfast and 46% lower after a standard caloric meal (SCM), compared to fasting conditions. Mean AUCinf was 42% higher after a HCHF breakfast mainly caused by one outlier and comparable after SCM (+8%). Median tmax of PHA-022121 was delayed by 2.25 h after a HCHF breakfast and by 0.50 h after SCM. Absorption was still fast and plasma levels reached levels that were 4xEC85 within 15 min.”

Source: [Crabbé et al. (2021)](https://ir.pharvaris.com/static-files/a5937e81-635a-4808-b099-3a049c87c51b)

<a id="topic-2.1.2.6.3-4"></a>

### Company summary of phase 1 pharmacokinetics with and without food

> “In our Phase 1 clinical trials to-date, we have observed rapid exposure and predictable linear pharmacokinetics (PK) with and without food.”
> “Exposure exceeds the anticipated threshold therapeutic plasma level (EC85) in 30 minutes, with or without food”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

<a id="topic-2.1.2.6.3-5"></a>

### Population pharmacokinetic model from the bradykinin challenge study

> “PK was analyzed using a two-compartment body model with first-order oral absorption and a lag time.”

Source: [Derendorf et al. (2020)](https://ir.pharvaris.com/static-files/33217945-6893-4f49-8a93-c80ea6fb2a31)

<a id="topic-2.1.2.6.3-6"></a>

### Immediate-release capsule 2 x 10 mg in healthy volunteers

> “Mean plasma levels >EC85 reached in 15 minutes after single dose of deucrictibant immediate-release capsule (2x10 mg)”
> “Mean plasma levels >EC85 maintained for ~12 hours after single dose of deucrictibant immediate-release capsule (2x10 mg)”

Source: [Maurer et al. (2023b)](https://ir.pharvaris.com/static-files/39663775-647d-44c4-8870-da48e883078f)

<a id="topic-2.1.2.6.3-7"></a>

### Immediate-release capsule in adults with HAE in a non-attack state (RAPIDe-1 part 1)

> “Pharmacokinetics were assessed in samples collected from 12 patients during Part 1. After administration of a single dose of the immediate-release capsule formulation, mean plasma levels of deucrictibant reached the drug concentration estimated to provide 85% maximal response (EC85; above which clinical effects are anticipated based on icatibant studies)25 of 13·8 ng/mL within 15-30 min of drug administration and were maintained for 8 h or longer (appendix p 24).”

Source: [Maurer et al. (2026)](https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026%2825%2900341-2/fulltext)

<a id="topic-2.1.2.6.3-8"></a>

### Immediate-release capsule 2 x 20 mg compared with the extended-release tablet 40 mg in healthy volunteers (PHA022121-C020)

> “Characterize the single-dose pharmacokinetics of deucrictibant XR tablet (40 mg) and deucrictibant IR capsule (2 x 20 mg) in healthy volunteers in a Phase 1, open-label, randomized, 2-period, crossover study (PHA022121-C020*).”
> “deucrictibant IR capsule (2 x 20 mg taken simultaneously) under fasting conditions.”
> “Deucrictibant IR resulted in a mean plasma concentration exceeding EC85 within 15-30 minutes.”
> “Mean t1/2 of deucrictibant was comparable for the XR tablet and IR soft capsules: 5.72 and 5.10 hours, respectively.”

Source: [Zhang et al. (2025)](https://ir.pharvaris.com/static-files/1680a98e-6898-4ee8-afb4-12d1ff5eb47a)

| Parameter | Deucrictibant IR capsule 2 x 20 mg | Deucrictibant XR tablet 40 mg |
| --- | --- | --- |
| Cmax, ng/mL, mean (SD) | “547 (193)” | “87.2 (25.5)” |
| tmax, hours, median (range) | “1.00 (0.50–1.50)” | “5.03 (3.98–24.00)” |
| AUCinf, ng⋅h/mL, mean (SD) | “1799 (745)” | “1547 (699)” |
| t1/2, hours, mean (SD) | “5.10 (1.28)” | “5.72 (1.70)” |
| CL/F, L/hours, mean (SD) | “26.5 (12.7)” | “31.5 (14.7)” |

Source: [Zhang et al. (2025)](https://ir.pharvaris.com/static-files/1680a98e-6898-4ee8-afb4-12d1ff5eb47a)

<a id="topic-2.1.2.6.3-9"></a>

### Half-life and peak concentration of the 20 mg immediate-release capsule compared with icatibant

> “Deucrictibant has a mean elimination half-life of approximately 5·1 h,34 compared with approximately 1·5 h for icatibant.35 Mean maximum plasma concentration is approximately 243 ng/mL by 0·5 h following a single 20 mg oral dose of deucrictibant immediate-release capsule25 and approximately 979 ng/mL by 0·75 h following a single 30 mg subcutaneous dose of icatibant.”
> “Mean plasma levels following a single 20 mg dose of deucrictibant immediate-release capsule achieved the EC85 of 13·8 ng/mL within 15–30 min of drug administration and were maintained for 8 h or longer,25 while the EC85 for icatibant has been estimated to be 54 ng/mL.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-2.1.2.6.3-10"></a>

### Adolescents: single-capsule pharmacokinetics in a non-attack state (RAPIDe-3)

> “Before random allocation, adolescent participants received a single oral deucrictibant capsule in a non-attack state for pharmacokinetic assessment.”
> “Pharmacokinetic analyses were performed on samples from ten adolescent participants in non-attack state. Following a single capsule of deucrictibant, mean plasma levels reached the concentration estimated to provide 85% maximal response (EC85) of 13·8 ng/mL within 15 min and were maintained through to at least the last measured time point of 8 h.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-2.1.2.6.3-11"></a>

### Multiple ascending doses of oral solution in healthy volunteers: accumulation, steady state, and half-life

> “PHA-022121 was well absorbed with median times to reach peak plasma levels within 1.00 to 1.75 h after dosing under fed conditions.”
> “Overall, Cmax and AUC0-12h on Day 1 and Day 10 were dose proportional over the investigated dose range of 12 to 50 mg BID PHA-022121 with a mean t1/2 ranging from 4.8 to 7.3 h after the Day 10 dose.”
> “Repeated dosing for 10 days resulted in about 1.0- to 1.6-fold accumulation in Cmax, Ctrough, and AUC for PHA-022121.”
> “At steady state, which was reached within 72 hours, plasma levels remained consistently above the therapeutic threshold (EC85) for all doses.”

Source: [Groen et al. (2021)](https://ir.pharvaris.com/static-files/f7f8b87d-c488-4611-b3a6-a2275aa94143)

<a id="topic-2.1.2.6.3-12"></a>

### Metabolism: CYP3A4 and an active metabolite

> “PHA-022121 is broken down by certain enzymes, among others by CYP3A4.”

Source: [Onderzoekmetmensen.nl NL-OMON49496](https://onderzoekmetmensen.nl/en/node/49496)

> “to assess steady-state PK of PHA-022121 and its active metabolite M2-D in the presence of a drug cocktail in healthy adult subjects.”

Source: [Onderzoekmetmensen.nl NL-OMON49587](https://www.onderzoekmetmensen.nl/en/node/49587)

<a id="topic-2.1.2.6.3-13"></a>

### Mass balance study and Japanese bridging study

> “Absorption, metabolism, and excretion (mass balance)”
> “to characterize the absorption, metabolism, and excretion”
> “Japanese PK bridging”
> “Double-blind, randomized, single oral dose, two-period crossover comparing pharmacokinetics between Japanese and Caucasian volunteers”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

## Related pages
- [Deucrictibant (PHA121): On-demand treatment of hereditary angioedema attacks](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Terms and abbreviations](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/terms-and-abbreviations.md)
- [Deucrictibant (PHA121): On-demand treatment of hereditary angioedema attacks](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/executive-summary) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/executive-summary.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Product information and disease description](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Clinical evidence](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/clinical-evidence.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Economic information and modeling report](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/economics) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/economics.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: References](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/references) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/references.md)
